U.S. Healthcare Services Stock News

Investors may be wondering whether CONMED at around US$38.10 is starting to offer value, or if the stock’s long slide still reflects unresolved risks. The share price recently closed at US$38.10, with a 3.9% move over 7 days and 10.3% over 30 days, against a year to date return of a 6.0% decline and a 1 year return of a 33.5% decline that sits on top of a 68.0% decline over 3 years and a 71.8% decline over 5 years. Those long term returns have sharpened focus on how investors are assessing...

AngloGold Ashanti (NYSE:AU) capped FY 2025 with fourth quarter revenue of US$3.1b and Basic EPS of US$1.68, rounding out a trailing twelve month run of US$9.9b in revenue and Basic EPS of US$5.19. Over the past six reported quarters, revenue has moved from US$1.5b in Q3 2024 to US$3.1b in Q4 2025, while quarterly Basic EPS stepped from US$0.53 to US$1.68 as net income excluding extra items shifted from US$223m to US$855m. With trailing net profit margins sitting at 26.6% compared with 17.3% a...

If you are wondering whether Carpenter Technology's recent share price puts the stock on sale or already prices in a lot of optimism, the valuation story is worth a closer look. At a last close of US$445.14, the stock shows returns of 4.0% over 7 days, 13.0% over 30 days, 31.6% year to date and 113.4% over 1 year, with a very large 3 year and 5 year return profile. Recent coverage has focused on Carpenter Technology's role in capital goods and aerospace related markets, with attention on how...

Investors may be asking whether Principal Financial Group at around US$100 per share is offering fair value or a potential mispricing opportunity right now. The stock has recently seen a 0.9% decline over 7 days, compared with stronger returns of 9.9% over 30 days, 11.9% year to date, 31.8% over 1 year, 62.3% over 3 years and 83.4% over 5 years. Recent coverage has focused on how investors are reassessing insurers like Principal Financial Group in light of broader sector trends and shifting...

Stock performance snapshot MBX Biosciences (MBX) has caught investor attention recently, with the stock showing an 8.1% move in the last day and a 14.9% gain over the past month, alongside a 1-year total return near 196%. That kind of run, combined with a market value around US$1.53b and clinical stage programs in endocrine and metabolic disorders, puts the spotlight on how much future progress in its pipeline might already be reflected in the current share price. See our latest analysis for...

In early May 2026, Galaxy Digital Inc. filed a US$500 million at-the-market follow-on offering and a roughly US$7.77 billion shelf registration covering up to 265,061,636 Class A shares plus a broad mix of other securities. Just days earlier, State Street Investment Management and Galaxy Asset Management launched the State Street Galaxy Onchain Liquidity Sweep Fund on Solana, underscoring Galaxy’s role in bringing tokenized cash management and stablecoin-based fund access to institutional...

CDW (NasdaqGS:CDW) has launched an AI first program called "Geared for Growth" across its operations and go to market model. The initiative seeks up to US$200 million in annual run rate savings targeted for 2027 to 2028. The program focuses on embedding AI into internal processes and customer facing activities to improve productivity and efficiency. CDW is a technology solutions provider, so an AI first shift sits directly in the flow of what customers are asking for across infrastructure,...

Wondering if Plains All American Pipeline at around US$22 is still offering value, or if most of the opportunity is already priced in. The stock last closed at US$22.09, with a 4% decline over the past week, a 0.7% decline over the past month, a 21.3% gain year to date and a 41.7% return over the past year. Recent coverage around Plains All American Pipeline has focused on its position within the energy infrastructure space and how investors are weighing income potential against exposure to...

Wondering if Paycom Software at around US$138 a share is a bargain or a value trap? This article walks through what the current price actually implies. The stock has shown a 9.2% return over the last 7 days and 11.4% over the last 30 days. Yet year to date it sits at a 9.2% loss and a 44.0% loss over the past year, which naturally raises questions about risk and potential recovery. Recent coverage has focused on how Paycom Software fits into the broader professional services and software...

Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch. See our latest analysis for Schrödinger. Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of...

ACM Research (ACMR) opened 2026 with Q1 revenue of US$231.3 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$960.2 million and EPS of US$1.40 that frame the latest quarterly print. Over the past six quarters, the company has seen quarterly revenue range from US$172.3 million to US$269.2 million and basic EPS move between US$0.12 and US$0.56, giving investors a clear view of how top line and per share earnings have tracked into the current TTM profile. With...

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...

Wondering if Labcorp Holdings at around US$258 a share still offers value, or if most of the opportunity is already priced in? This article walks through the key signals you can use to judge that for yourself. The stock has been fairly steady over the last week with a 0.5% return, has a 4.1% decline over the past month, yet sits on a 4.8% return over 1 year and 41.6% over 3 years. This raises the question of whether the current price reflects the business fundamentals. Recent headlines...

Ubiquiti (UI) has put up another big quarter, with Q2 2026 revenue of US$814.9 million and basic EPS of US$3.86, while trailing 12 month EPS sits at US$14.69 on revenue of about US$3.0 billion and earnings growth over that period is described as a 99.7% jump. The company has seen quarterly revenue move from US$599.9 million and EPS of US$2.26 in Q2 2025 to US$814.9 million and EPS of US$3.86 in Q2 2026, and trailing 12 month net profit margin is now stated at 29.9% versus 20.7% a year...

Wondering whether Clover Health Investments at US$2.82 is still a bargain or already pricing in its prospects? This breakdown will help you judge what you are really paying for. The stock has had a strong run over shorter periods, with returns of 2.5% over 7 days, 48.4% over 30 days and 17.0% year to date. However, the 1 year return sits at a 24.8% decline and the 3 year return is very large at 196.7% compared to a 61.2% decline over 5 years. Recent headlines have focused on the company as a...

Lyft (LYFT) closed FY 2025 with fourth quarter revenue of US$1,592.7 million and basic EPS of US$6.88, setting a high bar for a year in which trailing 12 month EPS reached US$6.92 and revenue stood at US$6.3 billion alongside very large year over year earnings growth and a 45% net profit margin. Over the past six quarters, the company has seen quarterly revenue move from US$1,522.7 million in Q3 2024 to between US$1,450.2 million and US$1,685.2 million across FY 2025, while basic EPS ranged...

CoreWeave (CRWV) has just wrapped up FY 2025 with Q4 total revenue of US$1.6b, a basic EPS loss of US$0.89 and net income loss of US$452.0m. This caps off a year in which trailing twelve month revenue reached US$5.1b alongside a TTM basic EPS loss of US$2.75. Over the past six reported quarters, the company has seen revenue move from US$584.0m in Q3 2024 to US$1.6b in Q4 2025. During the same period, quarterly basic EPS has ranged between a loss of US$0.22 and a loss of US$1.82, so the latest...

If you are wondering whether Murphy Oil at around US$38.27 is offering value or just riding momentum, the recent share performance gives you plenty to think about. The stock has seen a 1 year return of 88.2% and is up 17.8% year to date, despite shorter term pullbacks with a 7 day return showing an 8.4% decline and a 30 day return showing a 10.5% decline. Recent coverage has focused on Murphy Oil as part of broader conversations around US oil and gas stocks, with attention on how producers...

Genpact (G) has wrapped up FY 2025 with fourth quarter revenue of about US$1.3 billion and basic EPS of US$0.83, alongside trailing twelve month revenue of roughly US$5.1 billion and EPS of US$3.18, with earnings over the past year reported as growing 7.6%. Over recent periods the company has seen quarterly revenue move from US$1,248.7 million and EPS of US$0.81 in Q4 FY 2024 to US$1,319.3 million and EPS of US$0.83 in Q4 FY 2025. Trailing twelve month net income sits at US$552.5 million and...

In early May 2026, Ocugen reported first-quarter revenue of US$1.53 million alongside a net loss of US$19.18 million, while also closing a US$115 million private offering of 6.75% Convertible Senior Notes due 2034 and using about US$32.7 million to retire its Avenue loan. These updates both highlight Ocugen’s ongoing cash burn and materially improve its liquidity profile, with management indicating the new financing extends the company’s cash runway and supports continued advancement of its...

Slide Insurance Holdings (NasdaqGS:SLDE) has entered the California market with a new excess and surplus lines residential property insurance program. The company has written its first California policy, marking the start of its operations in one of the largest U.S. property insurance markets. For investors watching property insurers, California represents a complex and heavily scrutinized market, especially for residential coverage. By using an excess and surplus lines structure, Slide...

Recent performance snapshot Monte Rosa Therapeutics (GLUE) has drawn investor attention after recent share price moves, with the stock last closing at $19.81 and delivering a return of 15.7% over the past month. See our latest analysis for Monte Rosa Therapeutics. While the recent 15.7% one-month share price return has been strong, the 29.4% year-to-date share price return and very large one-year total shareholder return suggest that momentum has been building over a longer period. If you are...

Upwork (UPWK) has just wrapped FY 2025 with fourth quarter revenue of US$198.4 million and basic EPS of US$0.12, alongside net income of US$15.6 million. This rounds out a year where trailing twelve month revenue came in at US$787.8 million and EPS at US$0.87. Over recent quarters the company has seen revenue move from US$191.5 million in Q4 2024 to between US$192.7 million and US$201.7 million across FY 2025, while quarterly EPS has ranged from US$0.12 to US$0.28. This sets up a story that...